Epidermal growth factor (EGF) receptor-ligand based molecular staging predicts prognosis in head and neck squamous cell carcinoma partly due to deregulated EGF- induced amphiregulin expression.
BACKGROUND
Increased expression of epidermal growth factor receptor (EGFR) and its ligands is associated with poor prognosis and chemoresistance in many carcinoma types, but its role in head and neck squamous cell carcinoma (HNSCC) is unclear. Our aim was to clarify whether mRNA expression of EGFR-ligands was linked to prognosis and cisplatin resistance, and if so, which ligand was most important and how was the expression regulated.


METHODS
To examine the prognostic effect of EGFR-ligand expression, we analyzed tumorous mRNA expression in 399 HNSCC patients. The intracellular signaling pathways controlling epidermal growth factor (EGF)-induced amphiregulin (AREG) expression were examined in three oral squamous cell carcinoma (OSCC) cell lines. Effect of AREG on cisplatin resistance was examined by viability assays in four-, and by association in 11 OSCC cell lines.


RESULTS
The patients were divided into five groups according to the median mRNA expression levels of four EGFR ligands, i.e. AREG, EGF, heparin-binding EGF-like growth factor (HBEGF) and beta-cellulin (BTC). The number of increased-expressed EGFR-ligands were progressively correlated to five-year survival, even in advanced TNM-stage IV patients, where five-year mortality increased from 26 % if tumor expressed none to one EGFR-ligand, to 45 % in three to four ligand expressing tumors. Thus, staging the tumor according to these EGFR-ligand mRNA expression pattern completely out performed TNM staging in predicting prognosis. Multivariate analysis identified AREG as the dominating predictor, and AREG was overexpressed in OSCC compared to tumors from other sites. Both EGF and HBEGF stimulation induced strong AREG increase in OSCC cell lines, which was partially mediated by the extracellular signal-regulated kinase 1/2 pathway, and negatively regulated by p38, c-Jun N-terminal kinase, and phosphoinositide-3 kinase. Although increased AREG mRNA expression predicted unfavorable prognosis in platinum treated HNSCC patients, AREG did not mediate cisplatin resistance in the OSCC cell lines.


CONCLUSIONS
Increased tumorous mRNA expression of four EGFR ligands was progressively associated with poor prognosis in HNSCC. Thus, EGFR-ligands mRNA expression pattern may be a new prognostic biomarker. The tightly regulated EGF-induced AREG mRNA expression was partly lost in the OSCC cell lines and restoring its regulation may be a new target in cancer treatment.


BACKGROUND
Not applicable as the clinical data of the 498 HNSCC patients and their mRNA expression profiles were collected from the open TCGA database: http://cancergenome.nih.gov/cancersselected/headandneck .
Department of Oral Biology, University of Oslo, P.b. 1052, Blindern, Oslo, 0316, Norway.
Jian
J
Gao
Department of Oral Biology, University of Oslo, P.b. 1052, Blindern, Oslo, 0316, Norway.
Camilla H
CH
Ulekleiv
Department of Oral Biology, University of Oslo, P.b. 1052, Blindern, Oslo, 0316, Norway. t.s.halstensen@odont.uio.no.
Trond S
TS
Halstensen
Amphiregulin (AREG); Cisplatin resistance; Epidermal growth factor (EGF); Oral squamous cell carcinoma (OSCC)
J Biol Chem. 2004 Apr 2;279(14):14287-93
14742435
Br J Cancer. 2007 May 21;96(10):1569-78
17453000
Oncogene. 2000 Dec 27;19(56):6550-65
11426640
Nat Cell Biol. 2007 Dec;9(12):1392-400
18037882
J Biol Chem. 2002 Jul 26;277(30):26839-45
12016209
Int Rev Cell Mol Biol. 2014;313:145-78
25376492
Int J Oncol. 2006 Mar;28(3):705-13
16465376
Growth Factors. 2014 Oct;32(5):155-63
25257250
Nat Rev Cancer. 2005 Nov;5(11):845-56
16239904
Oncol Rep. 2016 Jun;35(6):3265-74
27108527
Oncol Rep. 2008 Jun;19(6):1557-64
18497965
Cancer Res. 2006 Jun 15;66(12):6129-38
16778186
Cell Mol Life Sci. 2009 May;66(10):1755-65
19337692
Curr Opin Genet Dev. 2000 Feb;10(1):120-7
10679388
Biochim Biophys Acta. 2011 Dec;1816(2):119-31
21658434
PLoS One. 2013;8(1):e54136
23382875
J Biol Chem. 2008 Jan 11;283(2):739-50
17942395
Eur J Oral Sci. 2009 Dec;117(6):663-8
20121928
Semin Cell Dev Biol. 2014 Apr;28:31-41
24463227
J Clin Invest. 2012 Jun;122(6):1951-7
22833868
FASEB J. 2008 Apr;22(4):954-65
18039929
Ann Intern Med. 1992 Sep 1;117(5):408-14
1503333
Cancer Res. 2003 Sep 1;63(17):5218-23
14500348
Mol Cancer Res. 2007 Aug;5(8):863-72
17699110
J Biol Chem. 2003 May 23;278(21):19245-56
12637505
Oral Oncol. 2006 Apr;42(4):381-90
16376136
Chin J Cancer. 2011 Jan;30(1):5-12
21192840
J Biol Chem. 2016 Mar 11;291(11):5528-40
26786109
Nature. 2015 Jan 29;517(7536):576-82
25631445
FEBS J. 2010 Jan;277(2):301-8
19922469
J Am Soc Mass Spectrom. 2003 Sep;14(9):1022-31
12954170
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
24399786
J Pathol. 2009 May;218(1):122-30
19197951
Biochem Biophys Res Commun. 2007 Mar 23;354(4):885-91
17274952
Proc Natl Acad Sci U S A. 1988 Sep;85(17):6528-32
3413110
Eur J Oral Sci. 2009 Oct;117(5):528-35
19758248
J Oral Pathol Med. 2013 Jan;42(1):26-36
22643066
Science. 1991 Nov 22;254(5035):1146-53
1659742